Notice of Intent to Publish a Funding Opportunity Announcement for NIH Brain Development Cohorts Biospecimen Access (X01 Clinical Trial Not Allowed)

Key Dates

RFA-DA-22-037 - Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)

RFA-DA-22-038 - Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)

PAR-22-137 - Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)

PAR-22-138 - Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)

RFA-OD-21-004 - Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)

NOT-AA-23-004 - Notice of NIAAA's Participation in NOT-DA-22-064

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute on Minority Health and Health Disparities (NIMHD)

National Institute on Alcohol Abuse and Alcoholism ( NIAAA ))

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

Office of Research on Women's Health (ORWH)

The National Institute on Drug Abuse intends to promote a new resource access program by publishing a Funding Opportunity Announcement (FOA) to seek applications for the following: NIH Brain Development Cohorts (NBDC) Biospecimen Access Program (X01- Clinical Trial Not Allowed). This FOA will allow investigators to apply for access to biological samples from the Adolescent Brain Cognitive Development^SM (ABCD) Study. By making these specimens available to the greater scientific community, this resource award seeks to maximize the scientific potential of the biospecimens collected in the ABCD Study and expand the scope of ABCD’s open science model, allowing scientists from around the world to utilize these specimens and enrich the child and adolescent health data being obtained from the ABCD Study.

No funds will be provided through this opportunity. Applicants will be responsible for costs associated with conducting the research and sample shipment. Applicants will need to submit proof of funding for costs of analyses and sample shipment at the time of application.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in Spring 2023 with an expected application due date in Summer 2023.

This FOA will utilize the X01 activity code. Details of the planned FOA are provided below.

This Notice encourages investigators with expertise and insights into this area of adolescent health and development to begin to consider applying to this new FOA. The planned FOA will utilize the X01 activity code to create a Resource Access Program that will allow domestic and international investigators to apply for access to biological samples from the ABCD Study. Available specimens include saliva, whole blood, serum, deciduous teeth, and DNA from either saliva or blood. Detailed information on the policy for obtaining study samples and the application and review processes may be found on NIDA's funding opportunity page at https://nida.nih.gov/funding/nida-funding-opportunities/nih-brain-development-cohorts-biospecimen-access-program. Applicants should visit this page before applying for access to biospecimens from the ABCD Study.

Responsive applications will explain how the proposed use of biospecimens relates to adolescent health objectives, and how results will inform the scientific community and/or public health policy. In addition, responsive applications will describe how the proposed study aims to make use of the unique nature of the ABCD Study design and biospecimens and will demonstrate a clear capacity and expertise to conduct the proposed analyses.

Applicants will be expected to:

• Prior to their X01 application - Submit a letter of intent in the form of a Biospecimen Availability Request at least 6 weeks prior to the submission deadline to determine whether there is sufficient quantity of samples required for the proposed study and to determine whether the proposed use of samples is consistent with the limitations of the subjects informed consents. This request will include participant characteristics, visit timepoints, and the type(s), numbers and volumes of samples being requested, as well as a clear justification. A Resource Availability and Impact Report will be provided from the NIH Brain Development Cohorts Team which should be included in the application as a Letter of Support, and which the applicant may include when applying for funding from other sources.

• In their X01 application - provide a detailed Research Plan and proof of funding by identifying the funding source and including relevant documentation in the application.

• Upon completion of their X01 analyses - submit their derived data to the ABCD Study data repository upon completion of analyses, making it available to the broader scientific community.

TBD

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization

Applications are not being solicited at this time.

Please direct all inquiries to:

Kimberly LeBlanc, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-4102
Email: [email protected]